Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone914-347-4300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$471.43 million
Profitability
Miscellaneous
Employees474
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable
Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions
What is Acorda Therapeutics' stock symbol?
Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."
How were Acorda Therapeutics' earnings last quarter?
Acorda Therapeutics Inc (NASDAQ:ACOR) issued its quarterly earnings results on Thursday, May, 2nd. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping the Zacks' consensus estimate of ($1.07) by $0.51. The biopharmaceutical company had revenue of $44.14 million for the quarter, compared to analyst estimates of $35.14 million. Acorda Therapeutics had a positive return on equity of 9.34% and a negative net margin of 1.40%. Acorda Therapeutics's quarterly revenue was down 58.4% compared to the same quarter last year. During the same period last year, the company posted $0.14 earnings per share. View Acorda Therapeutics' Earnings History.
When is Acorda Therapeutics' next earnings date?
What price target have analysts set for ACOR?
10 equities research analysts have issued 12 month target prices for Acorda Therapeutics' stock. Their forecasts range from $10.00 to $33.00. On average, they expect Acorda Therapeutics' share price to reach $20.2222 in the next twelve months. This suggests a possible upside of 99.0% from the stock's current price. View Analyst Price Targets for Acorda Therapeutics.
What is the consensus analysts' recommendation for Acorda Therapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 2 sell ratings, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acorda Therapeutics.
What are Wall Street analysts saying about Acorda Therapeutics stock?
Here are some recent quotes from research analysts about Acorda Therapeutics stock:
- 1. According to Zacks Investment Research, "Acorda beats on earnings and revenues in first-quarter 2019. The company got a huge boost with the approval of Inbrija in the United States, slightly before the scheduled time period. The drug is also under review in the EU with a decision expected soon. Inbrija was launched in February and registered its first sales in the first quarter. However, Acorda’s key multiple sclerosis drug Ampyra is facing a generic competition which is significantly hurting Acorda’s top-line. The company expects to see a persistent decline in Ampyra sales during the quarters ahead in 2019. Shares of Acorda have underperformed the industry in the year so far. Nonetheless, Acorda boasts a strong pipeline addressing a wide range of disorders. The restructuring initiative is also saving costs." (5/3/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating but raise our price target on ACOR to $20 from $19. On Thursday, Acorda reported 4Q18 financials and detailed future commercialization plans for Inbrija, including monthly WAC pricing of $950, ~25% higher than our projections. The company reported net Ampyra revenues of $64.2M, higher than consensus $46.8M, reflecting a steep decline from the prior quarter, but clearly not as bad as some expected (we were $75.8M). That said, we anticipate Amp revs to continue to decline and therefore do not include Amp sales in our valuation of ACOR shares. Going forward, we see Acorda’s fate being clearly in the hands of Inbrija for the next phase of growth." (2/15/2019)
- 3. JPMorgan Chase & Co. analysts commented, "Friday, HSGX disclosed that discussions with the FDA had informally concluded ultimately resulting in the suspension of NeoCart’s development. The FDA notified HSGX that the company would be required to run an additional clinical trial to submit the BLA for NeoCart. Given HSGX’s capital position, this is not feasible and HSGX decided to suspend NeoCart development. To that end, HSGX will now explore all strategic options. HSGX’s outcome creates a few takeaways, in our view, regarding the cartilage segment which we discuss below." (12/26/2018)
- 4. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We currently ascribe $570M to AMPYRA and $850M to INBRIJA on a risk-adjusted net present value (rNPV) basis, using an 85% probability of success and a 15% discount rate for INBRIJA along with a 12% discount rate for AMPYRA." (11/5/2018)
- 5. Jefferies Financial Group Inc analysts commented, "Q3 beat due to delayed launch of generic Amprya last qtr…however, IMS points to -40% Q3 reduction in TRx already and as expected. Key milestone for ACOR is potential approval of 5th PDUFA. Analysis below suggests probability of approval is incrementally higher given recent developments – but we are Hold due to fairly balanced risk/reward up and down on the scenarios. With Ampyra generic happening now as expected, focus shifts to approval of Inbrija and whether ACOR should remain a standalone or look to sell itself to maximize value. When asked on the call, mgmt. says they are regularly exploring all options to maximize shareholder value (though if they do an OUS partnership as guided we predict stock would go down based on less M&A likelihood)." (11/4/2018)
Has Acorda Therapeutics been receiving favorable news coverage?
News headlines about ACOR stock have been trending somewhat negative on Sunday, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Acorda Therapeutics earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term.
Who are some of Acorda Therapeutics' key competitors?
Some companies that are related to Acorda Therapeutics include Aerie Pharmaceuticals (AERI), Audentes Therapeutics (BOLD), Regenxbio (RGNX), Orchard Therapeutics (ORTX), Coherus Biosciences (CHRS), Rubius Therapeutics (RUBY), Alector (ALEC), Fate Therapeutics (FATE), Momenta Pharmaceuticals (MNTA), Sangamo Therapeutics (SGMO), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT), NanoString Technologies (NSTG), GENFIT S A/ADR (GNFT) and Voyager Therapeutics (VYGR).
What other stocks do shareholders of Acorda Therapeutics own?
Who are Acorda Therapeutics' key executives?
Acorda Therapeutics' management team includes the folowing people:
- Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 63)
- Mr. David Lawrence, Chief Technology officer, Chief of Bus. Operations & Principal Accounting Officer (Age 61)
- Ms. Lauren M. Sabella, Chief Commercial Officer (Age 58)
- Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 46)
- Dr. Burkhard Blank, Chief Medical Officer and Head of R&D (Age 64)
Who are Acorda Therapeutics' major shareholders?
Acorda Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (8.33%), Dimensional Fund Advisors LP (6.52%), Northern Trust Corp (2.01%), Acadian Asset Management LLC (1.92%), Clearbridge Investments LLC (1.64%) and Goldman Sachs Group Inc. (1.41%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Barry E Greene, Burkhard Blank, David Lawrence, Ian F Smith, Lauren M Sabella, Lorin Randall, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.
Which institutional investors are selling Acorda Therapeutics stock?
ACOR stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Spark Investment Management LLC, Pinebridge Investments L.P., Northern Trust Corp, California Public Employees Retirement System, ClariVest Asset Management LLC, New York State Common Retirement Fund and Principal Financial Group Inc.. Company insiders that have sold Acorda Therapeutics company stock in the last year include Andrew A Hindman, Burkhard Blank, David Lawrence, Ian F Smith, Lauren M Sabella, Lorin Randall, Ron Cohen and Scopia Capital Management Lp. View Insider Buying and Selling for Acorda Therapeutics.
Which institutional investors are buying Acorda Therapeutics stock?
ACOR stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Acadian Asset Management LLC, Man Group plc, Opaleye Management Inc., Diamond Hill Capital Management Inc., Dimensional Fund Advisors LP, Teacher Retirement System of Texas and Marshall Wace LLP. Company insiders that have bought Acorda Therapeutics stock in the last two years include Ron Cohen and Scopia Capital Management Lp. View Insider Buying and Selling for Acorda Therapeutics.
How do I buy shares of Acorda Therapeutics?
Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acorda Therapeutics' stock price today?
One share of ACOR stock can currently be purchased for approximately $10.16.
How big of a company is Acorda Therapeutics?
Acorda Therapeutics has a market capitalization of $489.00 million and generates $471.43 million in revenue each year. The biopharmaceutical company earns $33.68 million in net income (profit) each year or $1.82 on an earnings per share basis. Acorda Therapeutics employs 474 workers across the globe.
What is Acorda Therapeutics' official website?
How can I contact Acorda Therapeutics?
Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.
MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe ACOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
